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Objective: Assimilate evidence for interventions to ameliorate negative changes in physical 
performance, muscle strength, and muscle quantity in hospitalised older adults.  
Methods: We searched for articles using MEDLINE, Embase, CINAHL, and Cochrane library using terms 
for randomised controlled trials, older adults, hospitalisation, and change in muscle quantity, strength, 
or physical performance. Two independent reviewers extracted data and assessed risk of bias. We 
calculated standardised mean differences for changes in muscle function/quantity pre- and post-
intervention.  
Results: We identified 9805 articles; 9614 were excluded on title/abstract; 147 full texts were 
excluded. We included 44 studies including 4522 participants; mean age 79.1. Twenty-seven studies 
(n=3417) involved physical activity interventions; a variety were trialled. Eleven studies involved 
nutritional interventions (n=676). One trial involved testosterone (n=39), two involved Growth 
Hormone (n=53), one involved nandrolone (n=29), and another involved erythropoietin (n=141). 
Three studies (n=206) tested Neuromuscular Electrical Stimulation. Evidence for 
effectiveness/efficacy was limited. Strongest evidence was for multi-component physical activity 
interventions. However, all studies exhibited at least some concerns for overall risk of bias, and 
considering inconsistencies of effect sizes across studies, certainty around true effect sizes is limited.   
Conclusion: There is currently insufficient evidence for effective interventions to ameliorate changes 
in muscle function/quantity in hospitalised older adults. Multiple interventions have been safely 
trialled in heterogeneous populations across different settings. Treatment may need to be stratified 
to individual need. Larger scale studies testing combinations of interventions are warranted. Research 
aimed at understanding pathophysiology of acute sarcopenia will enable careful risk stratification and 
targeted interventions. 
Registration: The protocol was registered with the International Prospective Register of Systematic 




Sarcopenia is defined by low muscle strength with low muscle quantity/quality; additionally 
demonstrated low physical performance defines severe sarcopenia. Cut-offs are two Standard 
Deviations (SDs) below means of young healthy reference populations (1). Acute sarcopenia (acute 
muscle insufficiency) particularly affects hospitalised older adults (2, 3). Normally proceeded by 
stressor events, it is defined by acute declines in muscle quantity/quality and/or function (strength or 
physical performance) producing incident sarcopenia (3, 4). Previous reviews considered chronic 
sarcopenia treatment/prevention (5-7); strongest evidence exists for physical activity. Resistance 
training improves muscle quantity, strength, and physical performance in community-dwelling 
populations (8). Some trials demonstrated enhanced benefit of nutritional supplementation alongside 
(9). Large studies are underway evaluating combined nutritional and exercise interventions for chronic 
sarcopenia (10).  
 
It is unknown whether chronic sarcopenia interventions can treat acute sarcopenia. Mechanisms 
differ, which may affect treatment efficacy. Acute sarcopenia is associated with greater systemic 
inflammation and immune-endocrine dysregulation. Inflammation (acute or chronic) may blunt 
response to exercise or protein challenges (anabolic resistance), but this may be acutely/severely 
upregulated in acute sarcopenia (11). Acute sarcopenia follows an accelerated course (3); traditional 
treatments may not work fast enough. Additionally, community interventions may be unfeasible in 
hospital. This review aimed to identify trialled interventions for ameliorating negative changes in 
muscle quantity, strength, or physical performance in hospitalised older adults, and to 




Protocol and registration 
 
Protocol was agreed by all researchers and registered with Prospective Register of Systematic Reviews 
(PROSPERO) – CRD42018112021. Reporting is consistent with Preferred Reporting Items for 




We included randomised controlled trials (RCTs) and quasi-randomised controlled trials involving 
hospitalised patients ≥65 years-old, where pre- and post-intervention measurements of muscle 
quantity, strength, or physical performance were available. Post-intervention measures until 28 days 
post-intervention were included. We included physical activity, nutritional, pharmaceutical, or 
Neuromuscular Electrical Stimulation (NMES) trials. Exclusion criteria were: degenerative 
neuromuscular disorders; acute stroke; trials of parenteral nutrition, surgical technique/invasive 
procedure, chemotherapy/radiotherapy, or anaesthetic agents/techniques; no control group; lengths 
of stay less than two days. We included studies that measured muscle quantity using Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI), Dual Energy X-ray Absorptiometry (DXA), 
Bioelectrical Impedance Analysis (BIA), or ultrasound, muscle strength using handgrip strength, knee 
flexion, or knee extension, or physical performance using Short Physical Performance Battery (SPPB), 
gait speed, Timed Up and Go (TUG), or 6-Minute Walking Test (6MWT). There were no date or 




We searched electronic databases (MEDLINE, Embase, CINAHL, CENTRAL) on 16th January 2019; search 
repeated on 3rd April 2020. Grey literature was identified through Web of Science, Google Scholar, 
Clinicaltrials.gov, article references, and protocol citations. We contacted authors for information 
where necessary, including requesting age breakdown of data. If no response was obtained, a decision 




We used published and unpublished terms for study design (RCTs), population (older adults AND 
hospitalised) and outcome measures (muscle mass OR muscle strength OR physical performance) in 
our search. Full search strategy is available in the online supplement; this was reviewed and agreed 




Citations were imported into Microsoft Excel 2016. Duplicates were removed automatically/manually. 
Two reviewers independently screened titles and abstracts for inclusion (CW, ZM). Disagreements 
were resolved through discussion. Full texts were reviewed independently by the same reviewers; 




Data were extracted independently by two reviewers (CW, ZM) using a template (Microsoft Excel 
2016). Extracted data were country, study design, sample size and dropouts, sample characteristics 
(age, ethnicity, Body Mass Index – BMI, sex), speciality, intervention description (type of intervention, 
how delivered), intervention characteristics (timing of intervention, dosage), control group, outcome 
data, length of stay, and adverse events. Outcome data at baseline and follow-up to include muscle 
quantity, muscle strength, and physical performance were extracted.  
 
Risk of bias 
 
Two reviewers (CW, ZM) independently assessed risk of bias using Cochrane risk of bias tool. 
Conflicts were resolved by discussion. Risk of bias was collated using RevMan version 5.3 (12). 
 
Synthesis of results 
 
We summarised study and participant characteristics, and outcome data at baseline and follow-up 
using means/SDs in text and tables. Interventions were grouped by subtype and outcomes. All studies 
were included in narrative synthesis. If sufficient information was available to estimate Standardised 
Mean Differences (SMDs) of change scores, effect sizes were evaluated as described in statistical 
analysis section. Certainty of interventions with large effect sizes was evaluated using Grading of 




Correlations for outcome measures were calculated from studies reporting SDs of change scores and 
baseline/follow-up measures (14). Mean correlation for each outcome was used to estimate SD of 
change in outcomes in studies where this was not available. We calculated SMDs of change scores by 
dividing difference in change score between comparison and intervention groups by SD of change 
score in comparison group (15). Effect sizes were calculated to one decimal place and classified as no 
effect (≤0.1), small (0.2 – 0.4), medium (0.5 – 0.7), or large (0.8 or greater) (16). If more than one effect 
size was available for a single trialled intervention and outcome type, the larger was included. Meta-






We identified 9805 articles after duplicates removal. We excluded 9613 following title/abstract 
screening; 192 full texts assessed for eligibility. We excluded 148 full text articles due to mean age not 
more than one SD above 65 (n=56), no control group (n=10), follow-up over 28 days (n=12), no 
baseline measures (n=6), no measures meeting inclusion criteria (n=20), duplicate data (n=11), unable 
to obtain necessary data from authors (n=24), other intervention type (n=2), and non-hospitalised 
population (n=6) (Figure 1). We included 44 studies in narrative synthesis and 32 studies in effect size 
evaluation. 
 
 Study characteristics 
 
This review included 4522 participants (2160 control, 2362 intervention). Sample size per arm ranged 
from 7 to 232. Most studies were small; 52% (23/44) (17-40) included 30 or fewer participants per 
arm; only 9% (4/44) (41-43) included over 100 participants in both arms. Mean age across all studies 
was 79.1 years; 59% female. Of studies reporting BMI, 74% (20/27) (17, 18, 21, 23, 26-28, 31, 34, 35, 
38, 43-51) reported mean overweight (≥25) BMI; three studies reported mean obese (≥30) BMI in at 
least one arm (23, 39, 52). One study reported data on ethnicity (38). Two studies (45, 50) reported 
frailty prevalence in control and intervention arms by recognised definitions; a third reported mean 
frailty indices (37). Table 1 shows included studies’ details; full study characteristics and results are 
available online. Table 2 shows effect sizes separated by interventions and outcomes.  
 
 
Figure 1 – Flowchart demonstrating identification of included studies.  
All stages of screening and inclusion/ exclusion were performed in duplicate. Reasons for exclusion of 
articles reviewed as full texts are specified.  
 
Table 1 – Characteristics of all studies included in narrative synthesis.  
 













24/ 22 Early physiotherapy Handgrip 
Braun (37), 2019 Geriatric 
medicine 





de Morton (41), 
2007 
General medicine 126/ 110 Physiotherapy-designed 
exercises 
TUG 




Fioreb (20), 2017 Elective colorectal 
surgery 





7/ 14 Body weight supported 
treadmill training 
TUG 




12/ 13 Enhanced recovery Handgrip 
Knee extension 
Houborg (46), 2006 Elective colorectal 
surgery 
























McGowan b (36), 
2018 
Acute medicine 
for older people 
25/ 25 Pedal exerciser Knee extension 
Knee flexion 
Moseley (54), 2009 Orthopaedic 
rehabilitation 








131/ 150 Chair-based exercise 
and walking 
SPPB 



















24/ 21 Water exercise TUG 
Knee extension 
Raymond (42), 2017 Geriatric 
medicine 
232/ 236 High intensity group 
exercises 
TUG 
Said b (22), 2012 Geriatric 
rehabilitation 
24/ 22 Enhanced physical 
activity 
TUG 
Said b (56), 2018 Geriatric 
rehabilitation 




Sano (47), 2018 Elective 
orthopaedic 






Schwenk (57), 2014 Geriatric 
rehabilitation 
















29/ 33 High intensity exercise TUG 
Torres-Sánchez 
(23), 2017 
Respiratory 29/ 29 Pedal exerciser Knee extension 
Wnuk(17), 2016 Vascular 16/ 15 Backward walking 6MWT 
16/ 16 Forward walking 6MWT 
Nutrition 









14/ 13 Citrulline amino acid DXA ASMM 
Deer (38), 2019 General medicine 20/ 20  Whey protein SPPB 
DXA FFM 









Files (39), 2020 Critical care 11/ 11 Nitrate-rich beetroot 
juice 
SPPB 













Niccoli (26), 2017 Geriatric 
medicine 








21/ 21 EPA-enriched oral 
nutritional supplements 
BIA SMI 

















9/ 11 Growth hormone Knee extension 
DXA LBM 
Sloan (33), 1992 Orthopaedic 
surgery 





16/ 17 Growth hormone Knee flexion 
CT thigh CSA 
Zhang (60), 2019 Orthopaedic 
surgery 
33/ 44 EPO injections 
(females) 
DXA ASM 
25/ 39 EPO injection (males) DXA ASM 
Neuromuscular Electrical Stimulation 
Lopez-Lopez (52), 
2019 














48/ 20 Chair-based functional 
exercise 
Gait speed 
8/ 12 NMES and functional 
training 
Gait speed 
N=Participant numbers; TUG=Time up and go; SPPB=Short Physical Performance Battery; 6MWT=Six-
minute walk test; DXA=Dual-Energy X-Ray Absorptiometry; ASMM=Appendicular Skeletal Muscle 
Mass; BIA=Bioelectrical Impedance Analysis; FFM=Fat Free Mass; SMI=Skeletal Muscle Index; 
LBM=Lean Body Mass; CT= Computed Tomography; CSA=Cross-sectional Area; LoS=Length of hospital 
Stay; COPD=Chronic Obstructive Pulmonary Disease 
*= Studies where insufficient information was available to estimate the SMD  
bUnpublished data 
 
Table 2 – Summary of intervention effect by intervention type, outcome type, and effect size. 
 














































































Water exercise and 
physiotherapy + 20/ 24 +/- (18) + 20/ 24 +/- (18) 
Seated side tapping 
+++ 41/ 40 - (47) - 41/ 40 - (47) 


























































































Protein and exercise 
























 NMES in combination 
with exercise 





N=Participant numbers; con=comparison group; exp=intervention group; NMES=Neuromuscular 
electrical stimulation 
*=Effect sizes categorised as: no effect [-] (≤0.1), small [+] (0.2 – 0.4), medium [++] (0.5 – 0.7), or large 
[+++] (0.8 or greater) 
¥=Risk of Bias categorised according to overall risk as: low [+], some concerns [+/-], or high [-] 
 
Physical activity interventions 
 
Most studies (61%; 27/44) reported physical activity interventions. Eighty-nine percent (24/27) 
included physical performance (17-22, 34, 37, 38, 40-47, 50, 53-58) and 44% (12/27) included muscle 
strength (18, 23-25, 36, 43, 44, 46, 47, 54, 57, 58). One study reported muscle quantity change (38), a 
multi-arm trial including nutritional and pharmaceutical interventions. Trials were conducted in 
various settings including elective orthopaedic (18, 47), colorectal (20, 25, 46), orthopaedic 
rehabilitation (19, 21, 54, 58), vascular (17), and cardiac surgery (40, 44, 55), and geriatric (22, 24, 34, 
36, 37, 42, 43, 56, 57), respiratory (23), and general medicine (38, 41, 45, 53).  
  
A range of physical activity interventions were trialled; evidence for effect was limited. Interventions 
included strength and balance training (21, 38, 40, 44, 46, 56), early and/or increased mobilisation (17, 
20, 22, 24, 25, 41), group exercise (42), water exercise/physiotherapy (18), chair-based exercise (34, 
38), seated side-tapping (47), pedal exercisers (23, 36), and progressive weight-bearing exercise in 
orthopaedic rehabilitation (19, 54, 58), using specialised harnesses where appropriate. An 
individualised multimodal physical training programme involving resistance exercise using machines 
and/or weights and gait/balance training substantially improved physical performance (gait speed and 
SPPB) and muscle strength in one of the largest studies (43). Other trials of individualised physical 
training programmes (strength with or without aerobic exercise stratified by frailty/functional status) 
showed small effects on physical performance (37, 45, 53, 55, 57). Differences may relate to how 
interventions were delivered or adherence. The trial with the largest effect size reported adherence 
rates of 83.4 – 95.8% (≥90% exercises successfully performed each session) (43) compared to 59.7% 
(>3 sessions attended per week; offered daily) in another (57).  
 
Interventions that ameliorated reductions in physical performance in trial populations included 
backward walking (17), progressive exercises stratified by frailty (55), resistance and balance training 
(44),, chair-based resistance exercise (38), individually progressed lower limb and core strengthening 
exercise (45), individualised progressive resistance, balance, and walking exercises (43), and seated 
side-tapping (47). Interventions that ameliorated reductions in muscle strength included pedal 
exercise (23), individualised progressive resistance, balance, and walking exercises (43), and early 
mobilisation with enhanced recovery after surgery (25). A high-intensity physiotherapy-led group 
exercise programme was as efficacious as individual sessions; group exercise resulted in improved 




Eleven nutrition trials were identified. Populations included orthopaedic surgery (27, 59), geriatric (26, 
30), general (38, 48, 49, 51), and respiratory medicine (28, 29), and critical care (39). Six studies 
reported physical performance change (26, 38, 39, 48, 49, 51), seven muscle strength change (26-28, 
48, 49, 51, 59), and four muscle quantity change (27, 29, 30, 38). Most studies were small; only one 
included more than 45 patients per arm. Interventions included protein enriched foods (26, 48) or 
supplements (38, 49, 51), β-Hydroxy-β-MethylButyrate (59), oral nutritional supplementation (28), 
Eicosapentaenoic Acid (29), citrulline (30), nitrate-rich beetroot juice (49), and nutritional consultation 
(27). Three trials combined nutritional consultation to reach specified caloric/protein intake) with 
strength/resistance training (27, 38, 51). One study of progressive strength training followed by 
immediate protein supplementation showed statistically significant improved handgrip strength (51). 
Statistically significant improvements in physical performance were demonstrated comparing all 




Five trials involved pharmaceuticals; four in orthopaedic surgery populations. Pharmaceuticals 
included Growth Hormone (GH) (31, 32), steroid (nandrolone) (33), testosterone (38), and 
erythropoietin injections (60). All studies measured muscle quantity (DXA, CT, or BIA) and both GH 
trials measured muscle strength. The only study that measured physical performance was the multi-
arm study including physical activity and nutritional interventions (38). One GH trial showed 
statistically significant amelioration in muscle quantity loss by DXA (32) and the other showed 
statistically significant amelioration in knee flexion strength loss (31). Adverse events were similar 
between control and intervention arms (31); one study showed slightly higher peripheral oedema 
rates amongst GH recipients (32). The nandrolone trial did not report statistically significant results 
(33). Erythropoietin induced a small statistically significant amelioration in muscle quantity loss after 
orthopaedic surgery, not related to haemoglobin changes. Testosterone was safe in the multi-arm 
study, with statistically significant amelioration in physical performance demonstrated comparing all 
intervention groups to placebo (38).  
 
Neuromuscular electrical stimulation 
 
Three trials involved NMES (34, 35, 52); all combined NMES with exercise. One trial (geriatric medicine 
population) tested functional training alone against functional training with NMES (34). No statistically 
significant different change in gait speed between groups was demonstrated. Another trial 
(respiratory medicine population) showed significant lesser decline in knee extension strength with 
NMES (35). The third trial (general medicine population) resulted in significant improvements in 
physical performance with NMES (52). 
 
Risk of bias and certainty across studies 
 
Figure 2 shows overall risk of bias across studies. Full risk of bias details are shown in the online 
appendix. There were at least some concerns for overall risk of bias across most studies. Adherence 
to trial intervention was associated with lowest risk and selection of reported outcome with highest 
risk. Most common reason for high risk of bias related to randomisation processes. Over half of studies 
exhibited at least some concerns for selection of reported result. Table 3 shows assessment of 
certainty for two interventions (individualised physical training programmes and protein 
supplementation) across studies.  
 
 
Figure 2 – Risk of bias results across all included studies.  
 
 
Table 3 – GRADE domain certainty for individual physical training programmes and protein 
supplementation 
GRADE Domain Certainty Comments 
Individual physical training programme 
Risk of bias Moderate RCTs assessed were mainly considered to 
have some concerns for overall risk of bias; 
no studies with high risk of bias. 
Imprecision Moderate Meta-analysis of effect sizes across RCTs was 
not performed, although larger sample sizes 
in included studies. 
Inconsistency Low Inconsistency of effect sizes across studies. 
Indirectness High All but one study in geriatric medicine setting; 
all in older adults. All patients able to 
ambulate pre-admission and at risk of 
functional decline. 
Publication bias High Publication bias of RCTs unlikely, particularly 
as mixed results presented. Inclusion of thesis 
and conference abstract for another physical 
activity intervention included. 
Protein supplementation (with or without exercise) 
Risk of bias Moderate RCTs assessed were considered to have either 
low risk or some concerns for overall risk of 
bias. 
Imprecision Low Overall small number of studies with low 
sample sizes.  
Inconsistency Moderate Similar effect sizes demonstrated in small 
numbers of studies.  
Indirectness High All studies performed in general/geriatric 
medicine setting in older adults.  
Publication bias High Publication bias of RCTs unlikely, particularly 





Interpretation of findings 
 
Physical activity interventions were investigated more commonly than others. However, this mostly 
relates to studies with physical performance outcomes; only four trials not involving physical activity 
interventions measured physical performance (26, 39, 48, 49). Conversely, many physical activity trials 
reported muscle strength change but only one measured muscle quantity change, a multi-arm study 
also involving nutritional/pharmaceutical interventions. Nutritional and pharmaceutical trials focused 
on muscle strength and quantity changes rather than physical performance. This suggests disconnect 
in how physical activity interventions are trialled compared to other interventions; physical 
performance declines may not be prioritised as organ insufficiency markers in need of urgent 
treatment. 
 
Only nine trials reported muscle quantity change. This relates to historical reduced availability of 
feasible serial assessment tools; DXA, CT, and MRI remain gold-standard, but ultrasound is increasingly 
utilised (4, 61). As sarcopenia definition has developed, measures of muscle function are considered 
more important than muscle quantity (4). However, in acute sarcopenia, early muscle quantity 
declines may not be associated with muscle strength declines (3); preventing this may be important 
to prevent longer-term deteriorations. Additionally, muscle strength may be affected by fatigue/effort 
during acute illness making testing of efficacy/effectiveness challenging (62). Muscle quantity may be 
an appropriate treatment target in hospitalised patients; future trials of interventions for acute 
sarcopenia should consider incorporating in outcomes. Measurement of muscle quantity is also 
important to show biological effectiveness/mechanistic action.  
 
We identified several physical activity interventions that stratified treatment protocols individually 
(e.g. by frailty) (37, 43, 45, 53, 55). Most substantial and significant effects on muscle strength and 
physical performance were demonstrated in the highest reported adherence trial (43). Whilst this 
demonstrates high adherence of hospitalised older adults to complex trial designs is possible, 
effectiveness is expected to be reduced in clinical environments with limited compliance. Increasing 
mobilisation alone may be insufficient to prevent/treat acute sarcopenia (17, 20, 22, 24, 41), although 
this is safe to do when possible and should be commended (17, 20, 24, 25, 41). Physical activity 
interventions can be multidimensional and include resistance exercise (43, 44); it is safe and feasible 
to use machines/weights during acute phase of illness in hospitalised older patients (43, 44, 57). Pedal 
exercises (23, 36) and seated side-tapping (47) are simple, cheap, feasible, and potentially effective; 
these may be implemented as part of multidimensional stratified interventions. Group exercise may 
be as effective as individual exercise but more cost-effective (42). Group exercise has additional 
benefits of improving social interaction, and potentially improving motivation (63) and adherence 
(43). 
 
Several nutritional interventions were trialled. Although few trials showed statistically significant 
results, all trials were small and may have been under-powered for efficacy. Three trials combined 
nutritional intervention with physical activity (27, 38, 51). Research in chronic sarcopenia suggested 
additional protein supplementation may be most effective when combined with targeted physical 
activity i.e. resistance exercise (64). As inflammation and anabolic resistance are heightened with 
acute illness (3), greater doses (i.e. greater protein/amino acid intake) may be warranted in 
hospitalised older adults.  
 
Few studies tested pharmaceuticals. There is suggestion from GH trials that this may be effective in 
ameliorating reductions in muscle quantity and strength (31, 32). Further research is needed, including 
longer-term outcomes. Benefits of GH supplementation need to be balanced against adverse effects, 
although supplementation was safe in dosages used in these small studies. Research is ongoing into 
novel pharmaceutical agents for use in acute and chronic sarcopenia (65). Studies assessing 
correlations between immune-endocrine biomarkers and phenotypic changes in muscle quantity, 
quality, or function will enable stratified treatments and direct potential drug pathways.  
 
Trials of NMES showed conflicting results. NMES involves delivery of controlled electrical stimuli to 
superficial muscles via self-adhesive skin electrodes. These stimuli evoke muscle contractions, 
recruiting motor units and activating muscle fibres (66). NMES has been shown to ameliorate 
reductions in muscle quantity and function in healthy young volunteers during bedrest (67). It is 
plausible that NMES may treat acute sarcopenia in hospitalised older adults. However, in establishing 
effectiveness in clinical practice, adherence, physical activity impact, and which muscle groups to 
stimulate should be considered.  
 
What are the limitations of this review? 
 
This review included hospitalised adults over 65 years-old. We excluded younger adults to focus 
towards most vulnerable patients, who are most likely to benefit from targeted interventions. More 
studies were excluded for participant age than were included (56 vs. 44). This suggests persistent bias 
against involvement of older people in clinical trials, particularly those with frailty. Considering we 
included search terms for older people in our search, it is likely more trials involving younger adults 
were not identified, as well as trials excluded through abstract screening. Trials conducted in younger 
adults may be useful when developing interventions for acute sarcopenia in older adults, but caution 
should be taken extrapolating results from younger less heterogeneous populations.  
 
It is important to consider only three studies reported frailty status in both control and intervention 
arms (37, 45, 50). Frailty was measured in intervention arms but rates were not reported in studies 
that stratified by frailty (55, 57). Whilst important measures, handgrip strength and gait speed alone 
may be insufficient to diagnose pre-morbid frailty during acute illness (42). Recording levels of frailty 
prior to hospitalisation can ensure control and intervention arms are matched and enable sub-group 
analysis assessing treatment effect in individuals with and without frailty (45). Only one study reported 
ethnicity amongst participants (38). Normative values of muscle quantity may vary according to 
ethnicity (68), and muscle echotexture may differ (69). Further research is needed to assess effects of 
genetics and environment on ethnic differences, and how these relate to differences in muscle 
function and responsiveness to interventions. Without information on ethnicity within published 
trials, it is not possible to assess for between group differences.  
 
As described, majority of trials were small; many may have been underpowered to detect changes. 
Due to high heterogeneity in populations, interventions, and outcome measures, it was not possible 
to conduct meta-analyses. Some interventions that were not shown to be effective in small individual 
trials may be effective in larger powered studies. Additionally, most studies exhibited some concerns 
for risk of bias overall, and due to inconsistencies in effect sizes across different studies, there is limited 
certainty around true effect sizes. Many different outcome measures were also assessed across 
different RCTs. We consider that standardisation of assessment and outcome measures within 
geriatric medicine research will enable greater ease of knowledge transfer, sharing of datasets, and 
future meta-analyses of RCTs in ageing.  
 
It is important to consider that none of the included trials specifically included the presence of (acute 
or chronic) sarcopenia as inclusion criteria, or stratified treatment by sarcopenia. However, we 
consider that results of identified RCTs identified will be pivotal towards designing trials for prevention 
and/or treatment of acute sarcopenia. Acute sarcopenia is a rapidly progressing research area and 
therapeutic target. Twenty-two percent of studies (10/44) included in this review were published in 
the last 18 months. This demonstrates how rapidly progressive this area is, with increasing numbers 




Deteriorations in muscle quantity, strength, and physical performance are problematic in older adults 
following hospitalisation. However, insufficient evidence exists to enable targeted 
prevention/treatment strategies. A number of interventions have been trialled and shown to be safe 
for heterogeneous populations across various settings. Multidimensional physical activity 
interventions which are individually tailored (e.g. for frailty) have been trialled (43, 45, 55); the trial 
with most substantial effect size reported excellent adherence (43). Large scale multi-arm studies 
assessing effectiveness of combined interventions including physical activity (23, 43, 45, 47, 55), NMES 
(34), nutrition (59), and pharmaceuticals (31, 32) are warranted. Treatment may be most effective 
when stratified according to individual need. Treatment is likely to be guided by a combination of 
clinical and biological factors (e.g. immune-endocrine markers). Further research aimed at 
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